|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61P 3/10 | (2006.01) |
| A23L | (2006.01) | ||
| A23L 1/30 | (2006.01) | ||
| A61K | (2006.01) | ||
| A61K 31/122 | (2006.01) | ||
| A61K 31/201 | (2006.01) | ||
| A61K 31/202 | (2006.01) | ||
| A61P 3/14 | (2006.01) | ||
| A61P 9/00 | (2006.01) | ||
| A61P 11/00 | (2006.01) | ||
| A61P 13/04 | (2006.01) | ||
| A61P 13/12 | (2006.01) | ||
| A61P 15/00 | (2006.01) | ||
| A61P 17/02 | (2006.01) | ||
| A61P 17/06 | (2006.01) | ||
| A61P 19/02 | (2006.01) | ||
| A61P 25/00 | (2006.01) | ||
| A61P 25/08 | (2006.01) | ||
| A61P 25/16 | (2006.01) | ||
| A61P 25/18 | (2006.01) | ||
| A61P 25/20 | (2006.01) | ||
| A61P 25/22 | (2006.01) | ||
| A61P 25/24 | (2006.01) | ||
| A61P 25/28 | (2006.01) | ||
| A61P 25/32 | (2006.01) | ||
| A61P 27/02 | (2006.01) | ||
| A61P 29/00 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 1390025 |
| (13) | Kind of document | T |
| (96) | European patent application number | 02724475.5 |
| Date of filing the European patent application | 2002-05-09 | |
| (97) | Date of publication of the European application | 2004-02-25 |
| (45) | Date of publication and mention of the grant of the patent | 2005-03-30 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/GB2002/002148 |
| Date | 2002-05-09 |
| (87) | Number | WO 2002/096408 |
| Date | 2002-12-05 |
| (30) | Number | Date | Country code |
| 0113104 | 2001-05-30 | GB | |
| 0123446 | 2001-09-28 | GB |
| (72) |
HORROBIN, David Frederick, Kings Park House, GB
|
| (73) |
Laxdale Limited,
Kings Park House, Laurelhill Business Park, Polmaise Road, Stirling FK7 9JQ,
GB
|
| (54) | USE OF COENZYME Q (UBIQUINONE) AND EICOSAPENTAENOIC ACID (EPA) FOR THE TREATMENT OF NON-HODGKIN`S LYMPHOMA AND PSYCHIATRIC OR NEUROLOGICAL DISORDERS |
| USE OF COENZYME Q (UBIQUINONE) AND EICOSAPENTAENOIC ACID (EPA) FOR THE TREATMENT OF NON-HODGKIN`S LYMPHOMA AND PSYCHIATRIC OR NEUROLOGICAL DISORDERS |